BiochemistrybioRxiv
Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
Y. Unoh, S. Uehara, K. Nakahara…·Y. Tachibana
This paper describes the discovery of S-217622, an oral non-covalent SARS-CoV-2 3CL protease inhibitor showing antiviral activity and favorable pharmacokinetics in preclinical studies.
DOI 10.1021/acs.jmedchem.2c00117